β-Lactamase inhibitors are a class of pharmacological compounds administered in conjunction with β-lactam antibiotics to prevent their degradation by bacterial enzymes. These enzymes, known as β-lactamases, are produced by certain bacteria as a resistance mechanism; they catalyze the hydrolysis of the β-lactam ring, rendering the antibiotic biologically inactive.
Mechanism of Action
The primary function of a β-lactamase inhibitor is to bind to the β-lactamase enzyme, thereby protecting the co-administered antibiotic from enzymatic cleavage. Traditional inhibitors, such as clavulanic acid, sulbactam, and tazobactam, contain a β-lactam ring and act as "suicide inhibitors." They bind covalently to the active site of serine-based β-lactamases, causing an irreversible inhibition of the enzyme.
Newer generations of inhibitors, such as avibactam, vaborbactam, and relebactam, utilize different chemical structures (e.g., diazabicyclooctanes or boronic acid derivatives). These agents often demonstrate a broader spectrum of activity, including the ability to inhibit certain carbapenemases and extended-spectrum β-lactamases (ESBLs) that are resistant to older inhibitors.
Clinical Use
β-Lactamase inhibitors typically possess negligible intrinsic antibacterial activity and are therefore not used as monotherapy. Instead, they are formulated as fixed-dose combination products. Notable examples include:
- Amoxicillin/Clavulanic acid: Often used for respiratory tract infections and animal bites.
- Piperacillin/Tazobactam: A broad-spectrum combination used for severe healthcare-associated infections.
- Ceftazidime/Avibactam: Utilized for complicated intra-abdominal infections and urinary tract infections caused by multi-drug resistant Gram-negative bacteria.
Classification and Resistance
The effectiveness of an inhibitor depends on the specific class of β-lactamase produced by the pathogen, categorized by the Ambler classification system (Classes A, B, C, and D). While many inhibitors are effective against Class A enzymes (such as penicillinases), fewer are effective against Class B (metallo-β-lactamases) or certain Class D (oxacillinases) enzymes. Bacterial resistance to these combinations can still occur through mechanisms such as the hyperproduction of β-lactamases, mutations in the enzyme's active site, or changes in bacterial cell wall permeability (porin loss).
